IN8bio Shifts Focus to Leukemia Cell Therapy, Halts Glioblastoma Trial and Reduces Workforce

Trial Halt and Workforce Reduction:
IN8bio has halted its Phase 2 clinical trial for glioblastoma and laid off half of its workforce to focus on leukemia cell therapy. This strategic shift aims to allocate resources more efficiently towards promising areas of research.

Leukemia Cell Therapy Focus:
The company is redirecting its efforts towards developing gamma-delta T cell therapies for leukemia, indicating a significant change in its research priorities.

Previous Developments:
IN8bio had been conducting Phase 2 trials for INB-400 in newly diagnosed glioblastoma multiforme (GBM) and had also initiated Phase 1 trials for INB-200 in GBM and INB-100 in leukemia.

Orphan Drug Designation:
INB-400 and INB-410 had received orphan drug designation from the FDA for the treatment of malignant glioma, including newly diagnosed glioblastoma multiforme (GBM).

Clinical Updates:
The company had recently dosed the first patient in its Phase 2 clinical trial for INB-400 in GBM and had planned to present updated results from its Phase 1 study of INB-200 at the 2024 ASCO Annual Meeting.

Note:
The provided search results do not directly mention the halt of the Phase 2 glioblastoma trial or the workforce reduction. The information provided in the query seems to be a new development not covered in the given sources.